Cabozantinib potential option to treat differentiated thyroid cancer

According to results that will be presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium in Arizona this Friday, tumours treated with the drug shrunk in 97% of patients.Science Daily
Source: Society for Endocrinology - Category: Endocrinology Source Type: news